Effect of type I interferon on experimental autoimmune uveoretinitis in rats

References

• Baron S, Tyring SK, Fleischmann WR, Coppenhaver DH, Niesel DW, Klimpel GR, Stanton GJ, Hughes TK. The interferons: mechanisms of action and clinical applications. J Am Med Assoc 1991;266:1375–1383.
   PubMed Web of Science ®Google Scholar
• Borden EC. Interferons - expanding therapeutic roles. N Engl J Med 1992;326:1198–1205.
   Web of Science ®Google Scholar
• Gutterman JU. Cytokine therapeutics: lessons from interferon a. Proc Natl Acad Sci 1994;91:1198–1205.
   PubMed Web of Science ®Google Scholar
• Weinstock-Guttman B, Ransohoff RM, Kinkel RP, Rudick RA. The interferons: biological effects, mechanisms of action, and use in multiple sclerosis. Ann Neurol 1995;37:7–15.
   Google Scholar
• Arnason BGW. Interferon beta in multiple sclerosis. Clin Immunol Immunopathol 1996;81:I-I I.
   Google Scholar
• Dundar S, Ozcebe OI, Ozdemir 0, Kirazli S. Alpha-interferon in the treatment of Behçee s disease. In: Godeau P, Wechsler B, editors. Behçet's Disease. Amsterdam: Elsevier Science Publishers, 1993; 665–670.
   Google Scholar
• Durand JM, Kaplanski G, Telle H, Soubeyrand J, Paulo F. Beneficial effects of interferon-a2b in Behget's disease. Arth Rheumatol 1993;36: 1025–1026.
   Google Scholar
• Tsambaos D, Eichelberg D, Goos M. Behçet's syndrome: treatment with recombinant leukocyte alpha-interferon. Arch Dermatol Res 1986;278:335–336.
   Google Scholar
• Feron EJ, Rothova A, van Hagen PM, Baarsma GS, Suttorp-Schulten MSA. Interferon a2t, for refractory ocular Behçet's disease. Lancet 1994;343: 1428.
   Google Scholar
• K�tter I, D�rk H, Eckstein A, Zierhut M, Fierlbeck G, Saal JG. Erosive arthritis and posterior uveitis in Beh�et?s disease: treatment with interferon � and interferon �. Clin Exp Rheumatol 1996;14:313–315.
   PubMed Web of Science ®Google Scholar
• K�tter I, Eckstein AK, St�biger N, Zierhut M. Treatment of ocular symptoms of Beh�et?s disease with interferon �: a pilot study. Br J Ophthalmol 1998;82:488–494.
   PubMed Web of Science ®Google Scholar
• Nussenblatt RB, Kuwabara RT, Monasterio FM, Wacker WB. S-antigen uveitis in primates: a new model for human disease. Arch
   Google Scholar
• Caspi RR, Roberg FG, Chan CC, Wiggert B, Chader GJ, Rozenszajn LA, Lando Z, Nussenblatt RB. A new model of autoimmune disease: experimental autoimmune uveoretinitis induced in mice with two different retinal antigens. J Immunol 1988;140:1490–1495.
   PubMed Web of Science ®Google Scholar
• Redmond TM, Wiggert B, Robey FA, Nguyen NY, Lewis MS, Lee L, Chader GJ. Isolation and characterization of monkey interphotoreceptor retinoid-binding protein, a unique extracellular matrix component of the retina. Biochemistry 1988;24:787–793.
   Google Scholar
• Fukuda S, Fujii M, Koide K, Takimoto A, Yamamoto S, Aga M, Goto K, Kurimoto M. Large scale production and purification of natural murine interferon-a/B. Kagaku to Kogyo (Science and Industry, Tokyo)
   Google Scholar
• Van der Meide PH, Dijkema R, Caspers M, Vijverberg K, Schellekens H. Cloning, expression, and purification of rat IFN-ai. In: Pestka S, editor. Methods in Enzymology Volume 119: Interferons Part C. Orlando: Academic Press, 1986; 441–453.
   Google Scholar
• Okada AA, Sakai J, Usui M, Mizuguchi J. Intraocular cytokine quantification of experimental autoimmune uveoretinitis in rats. Ocul Immunol Inflamm 1998;6:111–120.
   PubMed Web of Science ®Google Scholar
• Gen� K, Dona DL, Reder AT. Increased CD80+ B cells in active multiple sclerosis and reversal by interferon �-1b therapy. J Clin Invest 1997;99:2664–2671.
   PubMed Web of Science ®Google Scholar
• Arnason BGW, Dayal A, Qu ZX, Jensen MA, Gen� K, Reder AT. Mechanisms of action of interferon-� in multiple sclerosis. Springer Semin Immunopathol 1996;18:125–148.
   PubMed Web of Science ®Google Scholar
• Mossman TR, Coffman RL. Th1 and Th2 cells: different patterns of lymphokine secretion leads to different functional properties. Annu Rev Immunol 1989;7:145–173.
   PubMed Web of Science ®Google Scholar
• Abreu SL. Suppression of experimental allergic encephalomyelitis by interferon. Immunol Commun 1982;11:1–7.
   PubMed Web of Science ®Google Scholar
• Abreu SL, Tondreau J, Levine S, Sowinski R. Inhibition of passive localized experimental allergic encephalomyelitis by interferon. Int Arch Allergy Appl Immunol 1983;72:30–33.
   PubMedGoogle Scholar
• Kuchroo VK, Martin CA, Greer JM, Ju ST, Sobel RA, Doft ME. Cytokines and adhesion molecules contribute to the ability of myelin proteolipid protein-specific T cell clones to mediate experimental allergic encephalomyelitis. J Immunol 1993;151:4371–4382.
   PubMed Web of Science ®Google Scholar
• Durelli L, Bongioanni MR, Cavallo R, Ferrero B, Ferri R, Ferrio MF, Bradac GB, Riva A, Vai S, Geuna M, Bergamini L, Bergamasco B. Chronic systemic high dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis. Neurology 1994;44:406–413.
   PubMed Web of Science ®Google Scholar
• Barton K, Lightman S. T lymphocyte effector mechanisms in the retina in posterior uveitis. Eye 1994;8:60–65.
   PubMed Web of Science ®Google Scholar
• Charteris DG, Lightman SL. Interferon-gamma (IFNy) production in vivo in experimental autoimmune uveoretinitis. Immunology 1992;75:463–467.
   PubMed Web of Science ®Google Scholar
• Barton K, McLauchlan MT, Calder VL, Lightman S. The kinetics of cytokine mRNA expression in the retina during experimental autoimmune uveoretinitis. Cell Immunol 1995;164:133–140.
   PubMed Web of Science ®Google Scholar
• Caspi RR, Sun B, Agarwal RK, Silver PB, Rizzo LV, Chan CC, Wiggert B, Wilder RL. T cell mechanisms in experimental autoimmune uveoretinitis: susceptibility is a function of the cytokine response profile. Eye 1997;11:209–212.
   PubMed Web of Science ®Google Scholar
• Saoudi A, Kuhn J, Huygen K, de Kozak Y, Velu T, Goldman M, Druet P, Bellon B. TH2 activated cells prevent experimental autoimmune uveoretinitis, a THI-dependent autoimmune disease. Eur J Immunol 1993;23: 3096–3103.
   Google Scholar
• Nakamura S, Yamakawa T, Sugita M, Kijima M, Ishioka M, Tanaka SI, Ohno S. The role of tumor necrosis factor-alpha in the induction of experimental autoimmune uveoretinitis in mice. Invest Ophthalmol Vis Sci 1994;35:3884–3889.
   Google Scholar
• de Kozak Y, Hicks D, Chatenoud L, Bellot J, Thillaye B, Faure JP. Intraocular TNF in endotoxin- and S-antigen-induced uveitis: in vitro synthesis of TNF by retinal Muller glial and pigment epithelial cells. Reg Immunol 1994;6:76–80.
   Google Scholar
• de Kozak Y, Naud MC, Bellot J, Faure JP, Hicks D. Differential tumor necrosis factor expression by resident retinal cells from experimental uveitis-susceptible and -resistant rat strains. J Neuroimmunol 1994;55:1–9.
   Google Scholar
• Luna JD, Chan CC, Derevjanik NL, Mahlow J, Chiu C, Peng B, Tobe T, Campochiaro PA, Vinores SA. Blood-retinal barrier (BBB) breakdown in experimental autoimmune uveoretinitis: comparison with vascular endothelial growth factor, tumor necrosis factor alpha, and interleukin-I beta-mediated breakdown. J Neurosci Res 1997;49:268–280.
   Google Scholar
• Dick AD, McMenamin PG, Korner H, Scallon BJ, Ghrayeb J, Forrester JV, Sedgwick JD. Inhibition of tumor necrosis factor activity minimizes target organ damage in experimental autoimmune uveoretinitis despite quantitatively normal activated T cell traffic to the retina. Eur J Immunol 1996;26:1018–1025.
   Google Scholar
• Phillips TM. Interferon-a induces renal dysfunction and injury. Curr Opin Nephrol Hypertens 1996;5:380–383.
   PubMedGoogle Scholar
• Dusheiko G. Side effects of alpha interferon in chronic hepatatis C. Hepatology 1997;26:1125–1215.
   Web of Science ®Google Scholar
• Chang LW, Liranzo M, Bergfeld WF. Cutaneous side effects associated with interferon-alpha therapy: a review. Cutis 1995;56: 144.
   Google Scholar
• Conlon KC, Urba WJ, Smith JW, Steis RG, Longo DL, Clark JW. Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy. Cancer 1990;65:2237–2242.
   PubMed Web of Science ®Google Scholar
• Antonelli G. Development of neutralizing and binding antibodies to interferon (IFN) in patients undergoing IFN therapy. Antiviral Res 1994;24:235–244.
   PubMed Web of Science ®Google Scholar
• Fleischmann M, Celerier P, Bernard P, Litoux P, Dreno B. Long-term interferon-alpha therapy induces autoantibodies against epidermis. Dermatology 1996;192:50–55.
   Google Scholar
• Pittau E, Bogliolo A, Tinti A, Mela Q, Ibba G, Salis G, Perpignano G. Development of arthritis and hypothyroidism during alpha-interferon therapy for chronic hepatitis C. Clin Exp Rheumatol 1997;15:415–419.
   Google Scholar
• Chung A, Older SA. Interferon-a associated arthritis. J Rheumatol 1997;24:1844–1845.
   PubMed Web of Science ®Google Scholar
• Guyer DR, Tiedeman J, Yannuzzi LA, Slakter JS, Parke D, Kelley J, Tang RA, Marmor M, Abrams G, Miller JW, Gragoudas ES. Interferon-associated retinopathy. Arch Ophthalmol 1993;III:350–356.
   Google Scholar